Navigation Links
ViroPharma Incorporated Honored by the National Organization for Rare Disorders
Date:5/18/2009

ress releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements in this press release include statements regarding ViroPharma's supplemental Biologics License Application for Cinryze for the treatment of acute attacks of HAE. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. There can be no assurance that the complete data from the open label study will demonstrate that Cinryze successfully treats all types of acute hereditary angioedema (HAE) attacks and may not be predictive of the results of any future testing. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a co
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... 15, 2014 ­ RedBrick Health , a fast-growing ... today announces that EmblemHealth , the ... is now providing the RedBrick Compass health assessment, combined ... all of its members. EmblemHealth is among the first ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... January 15, 2014 Two champions of ... their sponsorship of an annual competition for middle and ... access to, innovative STEM study. The competition presents students ... Tests of Engineering Aptitude, Mathematics, and Sciences is ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... Toronto Stock Exchange Symbol: MS, EDMONTON, Sept. 19 /PRNewswire-FirstCall/ ... treatment of multiple sclerosis (MS), today,announced that Mr. Kevin Giese, ... Conference in New York., WHEN: ... Grand Hyatt New York, New York, ...
... Keck Graduate Institute,(KGI) today announced that it ... learn the latest developments in mammalian cell culture,from ... undergone explosive growth over the,last 25 years," said ... Rathmann,Professor and director of the Amgen Bioprocessing Center ...
... Inc. (OTC Bulletin Board: YGYB; "Yongye" or the ... acid based,nutrients for plants and animals in the ... shareholders from the Company,s CEO and Chairman of,the ... events and plans,for the future., Dear Shareholders:, ...
Cached Biology Technology:BioMS Medical to present at UBS Global Life Sciences Conference 2KGI Offers Mammalian Cell Culture Program for Biotech Industry Professionals 2Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc. 2Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc. 3Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc. 4Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc. 5Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc. 6
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
(Date:4/17/2014)... the Amazon help create tinderbox conditions for wildfires ... forest loss during drought years, according to a ... in the Amazon could reach a "tipping point" ... to large-scale loss of trees, making recovery more ... Penn State. , "We documented one of the ...
(Date:4/17/2014)... The recent Yokahama IPCC meeting painted a stark warning ... which has a greenhouse effect 32 times that ... have shown that humic substances act as fully regenerable ... methane are held in wetlands instead of being released ... this system is disrupted it may enter into a ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... EVANSTON, Ill. --- A Northwestern University research team ... could be used to deliver chemotherapy drugs locally ... removed. The flexible microfilm device, which ... be customized easily into different shapes, has the ...
... planning of the preparatory activities for a new tentative ... satellite. On 7 September, preparatory activities for the ... Russia were stopped by Eurockot due to an anomaly ... and navigation subsystem of the launcher,s Upper Stage Breeze ...
... reveal an electromagnetic marker that predicts a patient,s ... "Such biomarkers that identify who will benefit ... minimize trial-and-error prescribing and speed delivery of care ... Carlos Zarate, M.D., of the National Institute of ...
Cached Biology News:Nanodiamond drug device could transform cancer treatment 2Nanodiamond drug device could transform cancer treatment 3Millisecond brain signals predict response to fast-acting antidepressant 2
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
... is a 2-color staining method for labeling ... detect apoptotic cells by flow cytometry. The ... for measuring apoptosis in cells, including positive ... performance; washing, reaction and rinsing buffers for ...
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
Biology Products: